Beena O. Pappen

1.7k total citations
19 papers, 1.1k citations indexed

About

Beena O. Pappen is a scholar working on Oncology, Biotechnology and Immunology. According to data from OpenAlex, Beena O. Pappen has authored 19 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 10 papers in Biotechnology and 10 papers in Immunology. Recurrent topics in Beena O. Pappen's work include Cancer Research and Treatments (10 papers), Immunotherapy and Immune Responses (10 papers) and CAR-T cell therapy research (5 papers). Beena O. Pappen is often cited by papers focused on Cancer Research and Treatments (10 papers), Immunotherapy and Immune Responses (10 papers) and CAR-T cell therapy research (5 papers). Beena O. Pappen collaborates with scholars based in United States and Japan. Beena O. Pappen's co-authors include John Nemunaitis, Neil Senzer, Phillip B. Maples, Padmasini Kumar, Daniel L. Shawler, Habib Fakhrai, Michael Nemunaitis, Casey Cunningham, Cynthia Bedell and Minal Barve and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Molecular Therapy.

In The Last Decade

Beena O. Pappen

19 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Beena O. Pappen United States 13 648 560 417 226 159 19 1.1k
Jan Martínek United States 7 397 0.6× 244 0.4× 492 1.2× 117 0.5× 91 0.6× 14 924
Alex W. Tong United States 16 448 0.7× 644 1.1× 298 0.7× 464 2.1× 172 1.1× 26 1.2k
Tobias Raum Germany 19 1.0k 1.6× 471 0.8× 716 1.7× 78 0.3× 73 0.5× 35 1.5k
Nahoko Suzuki Japan 8 393 0.6× 382 0.7× 505 1.2× 124 0.5× 49 0.3× 11 1.1k
Noweeda Mirza United States 10 819 1.3× 377 0.7× 1.1k 2.6× 84 0.4× 109 0.7× 16 1.5k
Mona Møller Norway 7 588 0.9× 364 0.7× 525 1.3× 65 0.3× 139 0.9× 7 964
Andrea Muscat Australia 11 384 0.6× 473 0.8× 232 0.6× 233 1.0× 54 0.3× 15 970
Doris Coleman United States 8 771 1.2× 883 1.6× 1.4k 3.3× 257 1.1× 92 0.6× 9 1.7k
Gavin Bendle United Kingdom 17 1.2k 1.8× 342 0.6× 1.0k 2.4× 397 1.8× 42 0.3× 29 1.5k
Elixabet Bolaños Spain 19 887 1.4× 290 0.5× 972 2.3× 146 0.6× 45 0.3× 33 1.4k

Countries citing papers authored by Beena O. Pappen

Since Specialization
Citations

This map shows the geographic impact of Beena O. Pappen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Beena O. Pappen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Beena O. Pappen more than expected).

Fields of papers citing papers by Beena O. Pappen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Beena O. Pappen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Beena O. Pappen. The network helps show where Beena O. Pappen may publish in the future.

Co-authorship network of co-authors of Beena O. Pappen

This figure shows the co-authorship network connecting the top 25 collaborators of Beena O. Pappen. A scholar is included among the top collaborators of Beena O. Pappen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Beena O. Pappen. Beena O. Pappen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Manning, Luisa, Minal Barve, Gladice Wallraven, et al.. (2017). Assessment of Low Dose Vigil® Engineered Autologous Tumor Cell (EATC) Immunotherapy in Patients with Advanced Solid Tumors. 2(1). 3 indexed citations
2.
Barve, Minal, Robert Mennel, Carl Lenarsky, et al.. (2016). Three-year Follow up of GMCSF/bi-shRNAfurin DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma. Molecular Therapy. 24(8). 1478–1483. 71 indexed citations
3.
Barve, Minal, Joseph A. Kuhn, Peter D. Beitsch, et al.. (2016). Follow-up of bi-shRNA furin / GM-CSF Engineered Autologous Tumor Cell (EATC) Immunotherapy Vigil® in patients with advanced melanoma. 1(4). 10 indexed citations
4.
Barve, Minal, Reva Schneider, Robert Mennel, et al.. (2015). Pilot Trial of FANG Immunotherapy in Ewing's Sarcoma. Molecular Therapy. 23(6). 1103–1109. 48 indexed citations
5.
Nemunaitis, John, Minal Barve, Douglas Orr, et al.. (2014). Summary of bi-shRNA<sup>furin</sup>/GM-CSF Augmented Autologous Tumor Cell Immunotherapy (FANG™) in Advanced Cancer of the Liver. Oncology. 87(1). 21–29. 41 indexed citations
6.
Nemunaitis, John, Neil Senzer, Minal Barve, et al.. (2014). Survival effect of bi-shRNAfurin/GMCSF DNA-based immunotherapy (FANG) in 123 advanced cancer patients to α-interferon-ELISPTOT response.. Journal of Clinical Oncology. 32(15_suppl). 3077–3077. 2 indexed citations
7.
Nemunaitis, John, Neil Senzer, Padmasini Kumar, et al.. (2013). Immune response and survival of refractory cancer patients who received TGF-β2 antisense/GM-CSF gene modified autologous tumor cell (TAG) vaccine. Gene Therapy. 20(9). 875–879. 7 indexed citations
8.
Nemunaitis, Gregory, Chris Jay, Phillip B. Maples, et al.. (2011). Hereditary Inclusion Body Myopathy: Single Patient Response to Intravenous Dosing of GNE Gene Lipoplex. Human Gene Therapy. 22(11). 1331–1341. 36 indexed citations
9.
Kumar, Padmasini, Yang Yu, Phillip B. Maples, et al.. (2011). Phase I Trial of TGF-β2 Antisense GM-CSF Gene-Modified Autologous Tumor Cell (TAG) Vaccine. Clinical Cancer Research. 17(1). 183–192. 43 indexed citations
10.
Maples, Phillip B., Padmasini Kumar, Yang Yu, et al.. (2010). FANG Vaccine: Autologous Tumor Cell Vaccine Genetically Modified to Express GM-CSF and Block Production of Furin. BioProcessing Journal. 8(4). 4–14. 24 indexed citations
11.
Rao, Donald D., Phillip B. Maples, Neil Senzer, et al.. (2010). Enhanced target gene knockdown by a bifunctional shRNA: a novel approach of RNA interference. Cancer Gene Therapy. 17(11). 780–791. 36 indexed citations
12.
Nemunaitis, Gregory, Phillip B. Maples, Chris Jay, et al.. (2010). Hereditary inclusion body myopathy: single patient response to GNE gene Lipoplex therapy. The Journal of Gene Medicine. 12(5). 403–412. 19 indexed citations
13.
Nemunaitis, John, Alex W. Tong, Michael Nemunaitis, et al.. (2009). A Phase I Study of Telomerase-specific Replication Competent Oncolytic Adenovirus (Telomelysin) for Various Solid Tumors. Molecular Therapy. 18(2). 429–434. 205 indexed citations
14.
Nemunaitis, John, Michael Nemunaitis, Neil Senzer, et al.. (2009). Phase II trial of Belagenpumatucel-L, a TGF-β2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients. Cancer Gene Therapy. 16(8). 620–624. 116 indexed citations
15.
Barve, Minal, James Bender, Neil Senzer, et al.. (2008). Induction of Immune Responses and Clinical Efficacy in a Phase II Trial of IDM-2101, a 10-Epitope Cytotoxic T-Lymphocyte Vaccine, in Metastatic Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 26(27). 4418–4425. 70 indexed citations
16.
Barve, Minal, Julia Glade Bender, Beena O. Pappen, et al.. (2008). Induction of immune responses and clinical activity in a phase II trial of IDM-2101, a 10-epitope CTL vaccine, in metastatic NSCLC patients. Journal of Clinical Oncology. 26(15_suppl). 8057–8057. 2 indexed citations
17.
Nemunaitis, John, Neil Senzer, Casey Cunningham, et al.. (2006). Phase I Trial of Sequential Administration of Recombinant DNA and Adenovirus Expressing L523S Protein in Early Stage Non-Small-Cell Lung Cancer. Molecular Therapy. 13(6). 1185–1191. 53 indexed citations
18.
Nemunaitis, John, Robert O. Dillman, Paul Schwarzenberger, et al.. (2006). 1104. Phase II Study of Lucanix™ a Transforming Growth Factor β2 (TGF-β2) Antisense Gene Modified Allogeneic Tumor Cell Vaccine in Non Small Cell Lung Cancer (NSCLC). Molecular Therapy. 13. S424–S425. 4 indexed citations
19.
Nemunaitis, John, Robert O. Dillman, Paul Schwarzenberger, et al.. (2006). Phase II Study of Belagenpumatucel-L, a Transforming Growth Factor Beta-2 Antisense Gene-Modified Allogeneic Tumor Cell Vaccine in Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 24(29). 4721–4730. 284 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jan Martínek Breakdown of academic impact, for papers by Alex W. Tong Breakdown of academic impact, for papers by Tobias Raum Breakdown of academic impact, for papers by Nahoko Suzuki Breakdown of academic impact, for papers by Noweeda Mirza Breakdown of academic impact, for papers by Mona Møller Breakdown of academic impact, for papers by Andrea Muscat Breakdown of academic impact, for papers by Doris Coleman Breakdown of academic impact, for papers by Gavin Bendle Breakdown of academic impact, for papers by Elixabet Bolaños
Rankless by CCL
2026